Meta-analysis: Among patients with intermediate-, high-, or very high-risk prostate cancer, the ideal duration of ADT with radiotherapy demonstrated nonlinear benefits, with diminished gains after 12 months and variation in benefit by risk group. ja.ma/4ppJBUq